Skip to main content

Table 3 Clinical characteristics, medical comorbidities and information about prostate cancer screening and serum PSA levels in cases and controls

From: The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria

Characteristics Cases (n = 50) Controls (n = 50)
n % n %
Age at prostate cancer diagnosis (years)     
    <50 1 2.0   
    50 - 59 4 8.0   
    60 - 69 20 40.0   
    70 - 79 25 50.0   
Reason for prostate cancer diagnosis     
    Abnormal PSA only 1 2.0   
    Abnormal PSA or DRE & Symptoms 5 10.0   
    Symptoms only 38 76.0   
    Don’t know 6 12.0   
Gleason score     
    4 - 6 12 24.0   
    7 16 32.0   
    8 - 10 18 36.0   
    Missing 4 8.0   
Serum PSA (ng/dl)*     
    <4 1 2.0 36 72.0
    4 - 9.9 5 10.0 9 18.0
    10 - 19.9 4 8.0 - -
    20 - 49.9 4 8.0 4 8.0
    50 - 135 31 62.0 - -
    Missing* 5 10.0 1 2.0
Prostate cancer screening     
    No screening (either PSA or DRE) - - 40 80.0
    PSA only or DRE only 8 16.0 4 8.0
    PSA and DRE (both) 41 82.0 6 12.0
    Unknown / missing 1 2.0 - -
Current health     
    Excellent 1 2.0 3 6.0
    Very Good 1 2.0 9 18.0
    Good 20 40.0 21 42.0
    Fair 25 50.0 15 30.0
    Poor 3 6.0 2 4.0
Comorbid conditions;     
    Asthma 1 2.0 3 6.0
    High blood pressure 21 42.0 30 60.0
    Stroke 1 2.0 2 4.0
    Diabetes 6 12.0 7 14.0
    High cholesterol - - 3 6.0
    Ulcers 2 4.0 6 12.0
    Chronic back pain 3 6.0 5 10.0
    Benign prostatic hyperplasia (BPH) 31 62.0 4 8.0
    Urinary tract infections/STD 2 4.0 2 4.0
Use of Traditional Medicine (Current) 11 22.0 12 24.0
Nr of physical exams (past 3 yrs); mean; sd 7.0 11.4 6.2 8.5
Nr of traditional healer visits; mean sd 9.4 17.8 1.7 2.7
  1. *For cases serum PSA indicates the diagnostic PSA, which was abstracted from medical records. For controls serum PSA levels were measured from the blood samples that they provided during in-person interview. One control did not provide a blood sample.